“SAHPRA has approved the implementation study,” the regulator said in response to Reuters questions, but added it was still reviewing its separate full market application.
The implementation study, similar to the final phase of a vaccine trial, will test the effects of the vaccine in the field after it is administered to around 350,000 to 500,000 health care workers.



























